Kowa Fuchs Endothelial Corneal Dystrophy Study K-321-303
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase III
- Conditions Being Studied: Fuchs Endothelial Corneal Dystrophy
Study Purpose
The purpose of this study is for those that have Fuchs Endothelial Corneal Dystrophy (FECD) and are planning to have cataract surgery and a procedure called descemetorhexis. The main goal of this study is to find out the effect of K-321 on how long it takes for your eyesight to improve during the first 12 weeks after cataract surgery and descemetorhexis.
Who Can Participate
Age: 18 years and older
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
UH Landerbrook Health Center
5850 Landerbrook Dr
Mayfield Heights OH, 44124
UH Westlake Health Center
960 Clague Rd
Westlake OH, 44145
- UH IRB: STUDY20230916
- StudyID: 2023-01180
- ClinicalTrials.gov: NCT05826353
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422